At OncoSil Medical, we are committed to making a positive change through the dedication and compassion of our team. This is why it is important that you get to know the people behind the logo.
We believe in our technology and its ability
to have a truly positive impact in Oncology.
First Commercial Pancreas Cancer Treatment With The OncoSil™ Device InRead more ...
OncoSil™ approved for Innovation Funding (NUB) and Central Ethics for all hospitals inRead more ...
The PanCO Study has been published in ESMO Open demonstrating the safety and efficacy benefits ofRead more ...
British Standards Institute (BSI) grants European CE marking for the OncoSil™ System and grantsRead more ...
We attended the E-AHPBA Conference in September 2021. Listen to experts discussing the PanCO StudyRead more ...
At OncoSil Medical we have a policy of continuous disclosure. We keep shareholders informed through ASX announcements, the company website, regular newsletters and our annual report. We encourage our shareholders to attend and participate at our annual general meetings.
OncoSil 2021 Annual Report
1. OncoSil™ is intended for intratumoural implantation into a pancreatic tumour via injection under endoscopic ultrasound guidance. OncoSil™ is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy.
Want to learn more?
OncoSil™ is a brachytherapy device that utilises targeted intratumoural placement of Phosphorous 32 microparticles, delivered via ultrasound-guided endoscopy.